Subscribe to RSS
Identification of Plasma Thrombopoietin Level and Its Significance in Patients with Aplastic Anemia and Myelodysplastic SyndromeFunding/Acknowledgments The study was funded by the National Natural Science Foundation of China (81370607, 81400085, 81400088, and 81170472).
Objective Our objective was to investigate the concentration of plasma thrombopoietin (TPO) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS), as well as its relationship with patients' responses to recombined human TPO (rhTPO) therapy.
Methods We detected the concentration of plasma TPO in 31 patients with AA, 27 patients with MDS, and 11 normal controls using enzyme-linked immunosorbent assay.
Results The median concentration of plasma TPO in patients with AA, MDS, and controls was (841.08 ± 768.64), (212.41 ± 338.93), and (35.09 ± 18.21) pg/mL, respectively. The TPO concentration in patients with AA and MDS was significantly higher than that in controls (p < 0.05). The median platelet (PLT) counts were (184 ± 34) ×109/L in the control group and (24 ± 19) ×109/L and (80 ± 71) ×109/L in AA and MDS patients, respectively. Negative correlations were found between plasma TPO concentration and PLT counts as well as megakaryocytes in bone marrow (p < 0.05). In AA patients treated with rhTPO, a negative correlation was observed between increased PLT counts and pretreatment TPO levels (p < 0.05).
Conclusion Plasma TPO concentration in AA and MDS was significantly higher than that in normal controls. Plasma TPO was negatively correlated with peripheral blood PLT counts and bone marrow megakaryocyte counts. The pretreatment TPO level may serve as a prognostic indicator for the therapeutic effect of rhTPO in AA patients.
The data used to support the findings of this study are available from the corresponding author upon request.
M.Z. and G.Z. contributed equally to this work.
All authors made substantial contributions to the intellectual content of this paper.
# Mengying Zhang and Gaochao Zhang contributed equally to this paper.
Article published online:
28 July 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Young NS. Aplastic anemia. N Engl J Med 2018; 379: 1643-1656
- 2 Cazzola M. Myelodysplastic syndromes. N Engl J Med 2020; 383: 1358-1374
- 3 Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339 (11) 746-754
- 4 Kaushansky K, Lok S, Holly RD. et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369 (6481) 568-571
- 5 Yoshihara H, Arai F, Hosokawa K. et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007; 1 (06) 685-697
- 6 Fielder PJ, Gurney AL, Stefanich E. et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87 (06) 2154-2161
- 7 de Sauvage FJ, Carver-Moore K, Luoh SM. et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183 (02) 651-656
- 8 Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265 (5177) 1445-1447
- 9 Ballmaier M, Germeshausen M, Krukemeier S, Welte K. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 2003; 996: 17-25
- 10 Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88 (07) 2578-2584
- 11 Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87 (02) 567-573
- 12 Usuki K, Tahara T, Iki S. et al. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996; 14 (05) 558-565
- 13 Zhang J, Wu Q, Zheng Y. Persistent elevated bone marrow plasma levels of thrombopoietin in patients with aplastic anemia. Cytokine 2016; 85: 11-13
- 14 Decker M, Leslie J, Liu Q, Ding L. Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance. Science 2018; 360 (6384) 106-110
- 15 Deng G, Yu S, Li Q. et al. Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia. Hematology 2017; 22 (03) 155-161
- 16 Seiki Y, Sasaki Y, Hosokawa K. et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica 2013; 98 (06) 901-907
- 17 Fontenay-Roupie M, Dupont JM, Picard F. et al. Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res 1998; 22 (06) 527-535
- 18 Feng X, Scheinberg P, Wu CO. et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011; 96 (04) 602-606
- 19 Wang H, Dong Q, Fu R. et al. Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy. BioMed Res Int 2015; 2015: 597293
- 20 Zhou K, Li Y, Li JP. et al. [Comparison of efficacy and safety of two different dose of recombinant human thrombopoietin regimens in severe aplastic anemia patients with immunosuppressive therapy]. Zhonghua Xue Ye Xue Za Zhi 2016; 37 (03) 205-209